Saw palmetto claim
This article was originally published in The Tan Sheet
Executive Summary
Petition for rehearing en banc denied for supplement marketers seeking a health claim linking saw palmetto to benign prostatic hyperplasia. The petition was filed on behalf of the plaintiffs by Washington, D.C. law firm Emord & Associates Feb. 19 (1"The Tan Sheet" March 1, 2004, p. 15). Julian Whitaker, MD, the American Association for Health Freedom, Pure Encapsulations, Durk Pearson and Sandy Shaw plan to petition for a writ of certiorari to the Supreme Court before June 7...You may also be interested in...
Saw Palmetto En Banc Appeals Court Re-Hearing Requested
A group of supplement marketers seeking approval of a health claim linking saw palmetto to treatment of benign prostatic hyperplasia have filed a petition for an en banc rehearing with the U.S. Court of Appeals
J&J To Power Ahead With 10 Launches In Four Years
Johnson & Johnson has achieved exceptional growth in recent years, and a raft of new products is set to sustain it further.
Bayer's Efforts To Pioneer Tumor-Agnostic Market In Europe Held Back
Bayer’s drive to lead a new market opportunity in Europe for histology-independent cancer agents like Vitrakvi has been set back by interim decisions from the UK’s NICE and Germany’s IQWiG, but there is a now a clear pathway to follow.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: